{"id":"NCT00710424","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy","officialTitle":"A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex in the Treatment of Subjects With Pain Due to Diabetic Neuropathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07","primaryCompletion":"2006-06","completion":"2006-06","firstPosted":"2008-07-04","resultsPosted":"2012-07-31","lastUpdate":"2023-05-03"},"enrollment":297,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Pain","Diabetic Neuropathy"],"interventions":[{"type":"DRUG","name":"Sativex","otherNames":["GW-1000-02"]},{"type":"DRUG","name":"Placebo","otherNames":["GW-4001-01"]}],"arms":[{"label":"Sativex","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in relieving pain due to Diabetic Neuropathy.","primaryOutcome":{"measure":"The Change From Baseline in Mean Diabetic Neuropathy Pain 0-10 Numerical Rating Scale Score at the End of Treatment (Average of Last 7 Days Treatment)","timeFrame":"Day 0 to Day 98","effectByArm":[{"arm":"Sativex","deltaMin":-1.67,"sd":2.13},{"arm":"Placebo","deltaMin":-1.55,"sd":2.09}],"pValues":[{"comp":"OG000 vs OG001","p":"0.634"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":26},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":149},"commonTop":["Dizziness","Nausea","Vomiting","Diarrhoea","Headache"]}}